Acute graft-versus-host disease (aGVHD) is a potentially fatal complication after allogeneic
hematopoietic cell transplantation (HCT), particularly for that with a HLA-mismatched donor.
Abatacept has been demonstrated as a potent drug to reduce the risk of aGVHD, but the
efficacy of subcutaneous form has yet been investigated. This trial is designed to
preliminarily determin the efficacy and saftey of subcutaneous abatacept in the prevention of
aGVHD after haplo-identical HCT.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University